Descriptive study of pneumococcal vaccination in cases of inflammatory disease: Analysis of practices - 05/06/22
Highlights |
• | Pneumococcal infections are frequent and potentially serious in patients with inflammatory diseases treated with immunosuppressants and/or biotherapies. |
• | This patient population, considered to be at very high risk of infection, is subject to nationwide vaccine recommendations. |
• | Current vaccination coverage against pneumococcus remains insufficient. |
• | It is important to consider measures to improve practices according to the possibilities of each care structure. |
Abstract |
Introduction |
Pneumococcal infections are frequent and potentially serious in patients with inflammatory diseases treated with immunosuppressants and/or biotherapies. This patient population considered to be at very high risk of infection is subject to national vaccination recommendations. The main objective of this study was to assess pneumococcal vaccine coverage in a day hospital (internal medicine and vascular disease) in patients treated with immunosuppressants.
Methods |
An observational, descriptive, retrospective, and single-center study. We included 150 consecutive patients for 3 months (February to April 2018). We studied pneumococcal vaccination coverage and the time elapsed between the date of vaccination with the 13-valent polysaccharide conjugate vaccine (PCV13) and the start of immunosuppressive therapy.
Results |
Among the 150 patients included in the study, vaccination coverage with PCV13 was 85% (127/150) and decreased to 46.7% (70/150) for the recommended vaccination schedule. Taking into account vaccine efficacy according to the date of initiation of the treatment, only 28.7% (43/150) of the patients in the study were able to benefit from an optimal complete vaccination schedule, i.e. 33.8% (43/127) among patients vaccinated with PCV13.
Conclusion |
Despite official recommendations, vaccination coverage against pneumococcus remains insufficient in patients under immunosuppressants and/or biotherapies. In addition to the continued training of doctors, optimizing computer prescription of vaccines in view of facilitating vaccination tracing and having vaccination carried out at the site of consultation are avenues for improvement to be considered.
Le texte complet de cet article est disponible en PDF.Keywords : Vaccination, Pneumococcal Infections, Immune System Diseases, Biological Therapy, Immunosuppressive Agents
Plan
Vol 52 - N° 3
P. 154-159 - mai 2022 Retour au numéro
Article précédent
- Prevalence and risk factors for gonococcal infection in Reunion Island
- A. Saïb, N. Bouscaren, B. Berçot, A. Duchateau, G. Miltgen, R. Rodet, G. Wartel, F. Andry, S. Iacobelli, A. Bertolotti
- First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022
- A. Maisa, G. Spaccaferri, L. Fournier, J. Schaeffer, J. Deniau, P. Rolland, B. Coignard, The regional COVID-19 investigation team, The EMERGEN consortium, A. Andrieu, O. Broustal, S. Chene, S. Chent, E. Fougère, G. Gbaguidi, M. Hamidouche, A. Lamy, Q. Mano, B. Mastrovito, A. Mercier, G. Modenesi, G. Picard, J. Prudhomme, F. Rapilly, A. Riondel, M. Rivière, B. Villegas Ramirez, A. Zhu-Soubise, M. Zurbaran, A. Amzert, L. Andreoletti, A. Bal, R. Beaurepere, S. Behillil, L. Belec, C. Bernard, L. Bocket, L. Bouri, T. Bourlet, C. Bressollette-Bodin, S. Brichler, C. Brugerolles, S. Cado, V. Calvez, N. Capron, S. Castelain, J. Castro-Alvarez, M.-L. Chaix, C. Charpentier, D. Che, C. Chillou, P. Colson, P. Coudene, A. Crinquette, A. De Rougemont, H. Delagrèverie, C. Delamare, T. Denecker-Berardino, D. Descamps, M. Desroches, G. Destras, G. Dos Santos, A. Ducancelle, S. Ducreux, T. Duret, V. Enouf, S. Fafi-Kremer, C. Felici, S. Fourati, P.-E. Fournier, C. Gaudy, H. Germain, V. Giordanengo, O. Gorge, S. Haim-Boukobza, C. Henquell, A. Holstein, L. Houhamdi, J. Izopet, V. Jacomo, A. Jacques, M.-C. Jaffar-Bandjee, M. Jimenez, L. Josset, S. Kemeny, M.-E. Lafon, A. Le Bars, G. Le Corguille, Q. Lepiller, A. Levasseur, N. Leveque, B. Lina, C. Madelaine, C. Malabat, S. Marque-Juillet, T. Martin-Dunavit, P. Mavingui, A. Merens, I. Messak, L. Morand-Joubert, X. Naudot, P. Neybecker, J.-M. Pawlotsky, L. Pilorge, J.-C. Plantier, C. Poggi, M. Pretet, C. Ragot, H. Raoul, S. Rogez, A.-M. Roque-Afonso, B. Roquebert, D. Rousset, F. Rozenberg, C. Sagot, S. Sahnoune, D. Salgado, O. Sand, C. Saudemont, E. Schvoerer, E. Simon-Loriere, R. Stephan, J. Sudour, V. Thibault, E. Tuaillon, A. Vabret, E. Vallee, S. Van Der Werf, J. Van Helden, L. Verdurme, A. Vignola, D. Wilkinson, Y. Yazdanpanah
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?